tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2025 Mar;19(3):e70081.
doi: 10.1111/irv.70081. Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024
Liliana Antunes[SUP] 1 [/SUP], Madelyn Rojas-Castro[SUP] 1 [/SUP], Marcos Lozano[SUP] 2 3 [/SUP], Iván Martínez-Baz[SUP] 3 4 [/SUP], Isabel Leroux-Roels[SUP] 5 6 [/SUP], Maria-Louise Borg[SUP] 7 [/SUP], Beatrix Oroszi[SUP] 8 [/SUP], Margaret Fitzgerald[SUP] 9 [/SUP], Ralf Dürrwald[SUP] 10 [/SUP], Ligita Jancoriene[SUP] 11 [/SUP], Ausenda Machado[SUP] 12 [/SUP], Goranka Petrović[SUP] 13 [/SUP], Mihaela Lazar[SUP] 14 [/SUP], Lenka Součková[SUP] 15 [/SUP], Sabrina Bacci[SUP] 16 [/SUP], Jennifer Howard[SUP] 1 [/SUP], Nuno Verdasca[SUP] 17 [/SUP], Luca Basile[SUP] 18 [/SUP], Jesús Castilla[SUP] 3 4 [/SUP], Silke Ternest[SUP] 5 [/SUP], Aušra Džiugytė[SUP] 7 [/SUP], Gergő Túri[SUP] 8 [/SUP], Roisin Duffy[SUP] 9 [/SUP], Carolin Hackmann[SUP] 10 [/SUP], Monika Kuliese[SUP] 19 [/SUP], Verónica Gomez[SUP] 12 [/SUP], Zvjezdana Lovrić Makarić[SUP] 13 [/SUP], Alexandru Marin[SUP] 20 [/SUP], Petr Husa[SUP] 15 [/SUP], Nathalie Nicolay[SUP] 16 [/SUP], Angela M C Rose[SUP] 1 [/SUP]; VEBIS SARI VE network team
Collaborators, Affiliations
We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.
Keywords: case–control study; elderly; severe acute respiratory infections (SARI); test‐negative design; vaccine effectiveness.
. 2025 Mar;19(3):e70081.
doi: 10.1111/irv.70081. Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024
Liliana Antunes[SUP] 1 [/SUP], Madelyn Rojas-Castro[SUP] 1 [/SUP], Marcos Lozano[SUP] 2 3 [/SUP], Iván Martínez-Baz[SUP] 3 4 [/SUP], Isabel Leroux-Roels[SUP] 5 6 [/SUP], Maria-Louise Borg[SUP] 7 [/SUP], Beatrix Oroszi[SUP] 8 [/SUP], Margaret Fitzgerald[SUP] 9 [/SUP], Ralf Dürrwald[SUP] 10 [/SUP], Ligita Jancoriene[SUP] 11 [/SUP], Ausenda Machado[SUP] 12 [/SUP], Goranka Petrović[SUP] 13 [/SUP], Mihaela Lazar[SUP] 14 [/SUP], Lenka Součková[SUP] 15 [/SUP], Sabrina Bacci[SUP] 16 [/SUP], Jennifer Howard[SUP] 1 [/SUP], Nuno Verdasca[SUP] 17 [/SUP], Luca Basile[SUP] 18 [/SUP], Jesús Castilla[SUP] 3 4 [/SUP], Silke Ternest[SUP] 5 [/SUP], Aušra Džiugytė[SUP] 7 [/SUP], Gergő Túri[SUP] 8 [/SUP], Roisin Duffy[SUP] 9 [/SUP], Carolin Hackmann[SUP] 10 [/SUP], Monika Kuliese[SUP] 19 [/SUP], Verónica Gomez[SUP] 12 [/SUP], Zvjezdana Lovrić Makarić[SUP] 13 [/SUP], Alexandru Marin[SUP] 20 [/SUP], Petr Husa[SUP] 15 [/SUP], Nathalie Nicolay[SUP] 16 [/SUP], Angela M C Rose[SUP] 1 [/SUP]; VEBIS SARI VE network team
Collaborators, Affiliations
- PMID: 40059069
- DOI: 10.1111/irv.70081
We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.
Keywords: case–control study; elderly; severe acute respiratory infections (SARI); test‐negative design; vaccine effectiveness.